FTC Eyes Evolving Pay-For-Delay Drug Deals
By Melissa Lipman ( September 1, 2011, 7:20 PM EDT) -- The Federal Trade Commission indicated Wednesday that it would take a hard-line approach to pay-for-delay deals in which brand-name drugmakers promise not to introduce their own generic treatments in exchange for competitors delaying entry to the market....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.